Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01094730 · ClinicalTrials.gov registry record · NA
Pilot Evaluation of a New Galyfilcon A Contact Lens Compared to a Marketed Galyfilcon A Contact Lens
A NA study of Myopia, sponsored by Johnson & Johnson Vision Care.
- Completed
- Registry status
- NA
- Development phase
- 185
- Enrollment target
- 9
- Study locations
NCT01094730: Completed NA study of Myopia, sponsored by Johnson & Johnson Vision Care.
NCT01094730 is a NA study of Myopia that has completed, run by Johnson & Johnson Vision Care. The registered enrollment target is 185 participants, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (30% lower). The trial reports 9 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01094730, a NA study of Myopia, has completed, sponsored by Johnson & Johnson Vision Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 185 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to compare lens surface characteristics and comfort between an experimental contact lens and a marketed contact lens.
Primary Outcome
Deposits on the front surface of each lens were examined by the investigator after 7 days of lens wear, and graded on a 5-point scale; 0 = no deposit, 1 = 1%-5% deposits, 2 = 6%-15% deposits, 3 = 16%-25% deposits, and 4 = 25% or more deposits. The grades were categorized into binary variable: grade 0 or 1 Vs. grade 2 or higher.
Conditions Studied
Interventions
- DEVICE galyfilcon A prototype lens
- DEVICE marketed galyfilcon A lens
Study Locations (9)
California
- - Cupertino
- - Huntington Beach
- - Los Angeles
- - Pismo Beach
Florida
- - Jacksonville
- - Orlando
Michigan
- - East Lansing
Ohio
- - Columbus
Texas
- - Amarillo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2010-02-01 |
| Est. Completion | 2010-04-01 |
| Phase | NA |
What the finished NCT01094730 record still lists
NCT01094730 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which galyfilcon A prototype lens is the first listed.
NCT01094730 lists 9 locations in 5 states (California, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT01094730 about?
NCT01094730 is a clinical study titled "Pilot Evaluation of a New Galyfilcon A Contact Lens Compared to a Marketed Galyfilcon A Contact Lens". The purpose of this study is to compare lens surface characteristics and comfort between an experimental contact lens and a marketed contact lens.
What is the current status of trial NCT01094730?
This trial is currently completed. It is a NA study. The enrollment target is 185 participants. The study started on 2010-02-01. Estimated completion is 2010-04-01.
What conditions does trial NCT01094730 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT01094730?
The interventions under investigation include: galyfilcon A prototype lens (DEVICE), marketed galyfilcon A lens (DEVICE).
Who is sponsoring clinical trial NCT01094730?
This trial is sponsored by Johnson & Johnson Vision Care, which has 142 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01094730 being conducted?
This trial has 9 study locations across California, Florida, Michigan, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01094730's enrollment target sits among peer trials
185 25th of 90 higher than 66 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI